Stingray Therapeutics is a biotech company that develops immunotherapies to treat various types of cancer.
Stingray Therapeutics has raised $6.6M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2023.
Stingray Therapeutics's investors include Propel(X), Newchip Accelerator, Health Wildcatters, THE CATALYTIC IMPACT FOUNDATION (CIF).
Stingray Therapeutics is headquartered in Houston, United States.
Stingray Therapeutics is a biotech company that develops immunotherapies to treat various types of cancer.
Stingray Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Stingray Therapeutics — Funding & Investors." VCBacked, March 31, 2023, https://www.vcbacked.co/company/stingray-therapeutics. Accessed July 20, 2026.
VCBacked. (2023). Stingray Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/stingray-therapeutics
{{cite web |title=Stingray Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/stingray-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated